AMGNHealthcare · Drug Manufacturers - GeneralThe 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $395 — -10.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Issuance (46): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −10.1% from it.
Of the 20 most recent actions, 13 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | Piper Sandler | Maintains | Overweight | $427 → $457 |
| 19 Aug 2026 | Argus Research | Maintains | Buy | $375 → $460 |
| 18 Aug 2026 | Cantor Fitzgerald | Maintains | Neutral | $350 → $400 |
| 18 Aug 2026 | Mizuho | Maintains | Neutral | $303 → $352 |
| 14 Aug 2026 | Barclays | Maintains | Equal-Weight | $360 → $380 |
| 10 Aug 2026 | Guggenheim | Maintains | Neutral | — |
| 10 Aug 2026 | Guggenheim | Maintains | Neutral | $343 → $388 |
| 7 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 7 Aug 2026 | Citigroup | Maintains | Neutral | $345 → $405 |
| 6 Aug 2026 | Bernstein | Maintains | Market Perform | — |
| 6 Aug 2026 | Bernstein | Maintains | Market Perform | $335 → $345 |
| 5 Aug 2026 | BMO Capital | Maintains | Outperform | — |
| 5 Aug 2026 | BMO Capital | Maintains | Outperform | $400 → $450 |
| 5 Aug 2026 | Oppenheimer | Maintains | Outperform | $400 → $450 |
| 5 Aug 2026 | Oppenheimer | Maintains | Outperform | — |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $370 → $400 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 5 Aug 2026 | Scotiabank | Maintains | Sector Outperform | — |
| 5 Aug 2026 | Scotiabank | Maintains | Sector Outperform | $385 → $450 |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $420 → $452 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMGN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 21% of US stocks
Cheaper than 5% of US stocks
Cheaper than 21% of US stocks
Higher than 51% of US stocks
Higher than 79% of US stocks
Higher than 84% of US stocks
Higher than 90% of US stocks
Higher than 84% of US stocks
Higher than 96% of US stocks
Higher than 90% of US stocks
Higher than 51% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Amgen (AMGN) as a strong momentum stock, noting that its Style Scores can help investors identify top-rated stocks based on their investing style.
Why it matters — AMGN watchers would care because the piece positions the company favorably by pointing out its strong momentum characteristics among Zacks-ranked stocks.
The article reports that biotech ETFs are experiencing a strong rally fueled by innovation, obesity drugs, and mergers and acquisitions, highlighting three funds that offer diversified exposure to the sector's growth.
Why it matters — As a major biotech company, Amgen stands within the sector whose positive momentum and innovation-driven conditions are highlighted in this piece.
The article highlights that among U.S. large-cap drugmakers, one name has clearly outperformed the pack so far in 2026, comparing Merck, Pfizer, and Amgen's stock performance.
Why it matters — Amgen watchers would care because the piece assesses how Amgen's 2026 stock performance stacks up against major pharmaceutical peers.
A Zacks Investment Research article, "Here's Why Amgen (AMGN) is a Strong Growth Stock," suggests investors can identify market-beating stocks using Zacks Style Scores. The piece frames Amgen as a strong growth stock according to this framework.
Why it matters — Amgen watchers would care because the article labels the company as a strong growth stock using Zacks' ranking methodology, highlighting its perceived growth characteristics.
The article outlines a framework for building a SWAN (Sleep Well At Night) income portfolio aimed at retirees and income investors, emphasizing consistent income, growth, and lower volatility through diversification and strategic planning. It advocates proven strategies over popular investments amid a potentially overvalued market, recommending a multi-bucket long-term portfolio adaptable to individual needs.
Why it matters — AMGN watchers would care because the article discusses general income-portfolio strategies and stock-selection criteria that could inform whether dividend-paying holdings like Amgen fit within such retirement-focused portfolios.
The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $395, with estimates ranging from $230 to $457. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 34 analysts covering Amgen, Inc., 14 rate it a Buy, 16 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 92 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Amgen, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 34 analysts implies -10.1% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 92 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $457 over the next 12 months.
Amgen, Inc. returned +54.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Amgen Inc. is a global biotechnology company that develops, manufactures, and commercializes human therapeutics for serious diseases.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Here's Why Amgen (AMGN) is a Strong Momentum Stock". Zacks Investment Research highlights Amgen (AMGN) as a strong momentum stock, noting that its Style Scores can help investors identify top-rated stocks based on their investing style.
Amgen Inc. is a global biotechnology company that develops, manufactures, and commercializes human therapeutics for serious diseases. Its portfolio centers on biologic medicines and specialty therapies used in oncology, inflammation, cardiovascular disease, bone health, nephrology, and rare diseases. The company also markets biosimilars that provide alternatives to established biologic drugs, expanding its presence across major pharmaceutical categories. Amgen serves healthcare providers, hospitals, clinics, pharmacies, and wholesalers in markets around the world, with products distributed through both institutional and commercial channels. Its current business is built around discovering and delivering treatments that address high unmet medical needs, making Amgen a significant player in the biopharmaceutical sector and a key provider of advanced medicines within modern healthcare markets.
CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com